Optimer Pharmaceuticals, Inc. (OPTR) - NASDAQ
OPTR is defunct.
  • May 9, 2013, 4:11 PM
    Optimer Pharmaceuticals (OPTR): Q1 EPS of -$0.65 misses by $0.06. Revenue of $19.4M misses by $1.69M. (PR)
    | May 9, 2013, 4:11 PM
  • May 9, 2013, 12:10 AM

    Notable earnings after Thursday’s close: AGO, AIRM, AL, ALIM, ANAC, ASYS, AUQ, BCEI, BID, BPZ, CALL, CPE, DAR, EGY, ET, FTK, FXEN, GXP, KTOS, LLNW, MBI, MCP, MDRX, MDVN, NGVC, NVDA, OPTR, PANL, PCLN, PDLI, PSA, RNDY, SF, SLXP, SQNM, TNGO, UBNT, ZGNX

    | May 9, 2013, 12:10 AM
  • May 8, 2013, 5:35 PM

    Notable earnings after Thursday’s close: AGO, AIRM, AL, ALIM, ANAC, ASYS, AUQ, BCEI, BID, BPZ, CALL, CPE, DAR, EGY, ET, FTK, FXEN, GXP, KTOS, LLNW, MBI, MCP, MDRX, MDVN, NGVC, NVDA, OPTR, PANL, PCLN, PDLI, PSA, RNDY, SF, SLXP, SQNM, TNGO, UBNT, ZGNX

    | May 8, 2013, 5:35 PM
  • Apr. 3, 2013, 11:31 AM

    Cubist Pharmaceuticals (CBST -3.1%) falls after Cantor Fitzgerald says the company's development of a competing product indicates it likely isn't preparing to bid for Optimer Pharmaceuticals (OPTR +0.1%). Analyst Irina Rivkind downgraded the stock to Sell Wednesday. (See: Optimer surges on takeover chatter)

    | Apr. 3, 2013, 11:31 AM
  • Apr. 2, 2013, 10:02 AM
    Optimer Pharmaceuticals (OPTR) surges 18.1% following a report that the antibiotics maker has attracted takeover interest from GlaxoSmithKline (GSK), AstraZeneca (AZN), Cubist Pharmaceuticals (CBST) and Japan's Astellas. Optimer hopes to fetch up to $1B in an auction, well above its market cap of $660M. The company has one drug on the market, Dificid, which is used to treat intestinal infections in hospitalized patients.
    | Apr. 2, 2013, 10:02 AM | 1 Comment
  • Feb. 28, 2013, 4:23 PM
    Optimer Pharmaceuticals (OPTR): Q4 EPS of $0.02. Revenue of $19.5M beats by $1.45M. (PR)
    | Feb. 28, 2013, 4:23 PM
  • Feb. 28, 2013, 12:10 AM
    Notable earnings after Thursday’s close: AIRM, AL, ALSK, BID, CLNE, CPNO, CRM, DECK, DRH, ENDP, GPS, GXP, HTGC, JOE, KOG, KYAK, MCP, MDR, MDVN, MENT, MTZ, MXWL, NGD, NOG, OPTR, OVTI, PANW, RNDY, RST, SD, SLXP, SONS, SPLK, SSRI, TEG, TESO, UHS, WR, XTEX, YOKU
    | Feb. 28, 2013, 12:10 AM
  • Feb. 27, 2013, 5:35 PM
    Notable earnings after Thursday’s close: AIRM, AL, ALSK, BID, CLNE, CPNO, CRM, DECK, DRH, ENDP, GPS, GXP, HTGC, JOE, KOG, KYAK, MCP, MDR, MDVN, MENT, MTZ, MXWL, NGD, NOG, OPTR, OVTI, PANW, RNDY, RST, SD, SLXP, SONS, SPLK, SSRI, TEG, TESO, UHS, WR, XTEX, YOKU
    | Feb. 27, 2013, 5:35 PM | 1 Comment
  • Feb. 27, 2013, 12:55 PM
    Midday top 10 gainers: ZGNX +39%. UNXL +24%. FSGI +21%. GWRE +18%. ELMD +16%. PDCE +14%. OPTR +13%. DLTR +12%. END +11%. SHI +11%.
    Midday top 10 losers: AH -26%. CBB -23%. AMBO -22%. RNIN -21%. CBMX -19%. XWES -19%. FSLR -16%. CMGE -15%. CRMB -13%. PRPH -12%.
    | Feb. 27, 2013, 12:55 PM
  • Feb. 27, 2013, 10:31 AM

    Optimer Pharmaceuticals (OPTR +15%) says its board of directors has begun exploring a full range of strategic alternatives and has engaged JPMorgan and Centerview Partners as financial advisers. The board stated however, that there are no assurances that the review will result in any action and that there would be no further comment on the process until it's completed. The company also preannounced Q4 results of $0.02 per share, and appointed its chairman, Dr. Henry McKinnell, as CEO.

    | Feb. 27, 2013, 10:31 AM
  • Feb. 27, 2013, 8:28 AM
    Optimer Pharmaceuticals, Inc. (OPTR): Q4 EPS of $0.02 may not be comparable to consensus of by -$0.38. Gross product sales of $21.3M. Shares +11.5% premarket. (PR)
    | Feb. 27, 2013, 8:28 AM
  • Jan. 4, 2013, 5:50 PM
    After-hours top gainers, as of 5:15 p.m.: OPTR +16%. GTI +9%. DSLV +3%. EGLE +2%. GNMK +2%.
    After-hours top losers: MSPD -8%. CFFN -5%. G -4%. PL -4%. WCRX -2%.
    | Jan. 4, 2013, 5:50 PM
  • Nov. 1, 2012, 5:15 PM
    Optimer Pharmaceuticals (OPTR): Q3 EPS of -$0.56 beats by $0.08. Revenue of $17.9M (+6.1% Y/Y) beats by $1.9M. (PR)
    | Nov. 1, 2012, 5:15 PM
  • Jul. 31, 2012, 5:43 PM
    Optimer Pharma (OPTR): Q2 EPS of -$0.01 beats by $0.06. Revenue of $49.8M (+150809.1% Y/Y) beats by $0.33M. Shares -4.8% AH. (PR)
    | Jul. 31, 2012, 5:43 PM
  • May 10, 2012, 4:28 PM
    Optimer Pharmaceuticals (OPTR): Q1 EPS of -$0.23 may not be comparable to consensus of $-0.40. Revenue of $14.4M (-79.2% Y/Y) misses by $14M. (PR)
    | May 10, 2012, 4:28 PM
  • Apr. 9, 2012, 9:05 AM

    Premarket gainers: AOL +35%. GOLD +7%. SCLN +4%.
    Losers: MOH -22%. HOGS -11%. OPTR -5%. RDN -4%. AVP -4%. ALU -4%. DRYS -3%. S -3%. X -3%.

    | Apr. 9, 2012, 9:05 AM
Company Description
Currently, there's no company description for OPTR.
Sector: Healthcare
Industry: Biotechnology
Country: United States